# A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

> **NCT01772472** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1486 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** trastuzumab
- **DRUG:** trastuzumab emtansine

## Key facts

- **NCT ID:** NCT01772472
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-03
- **Primary completion:** 2018-07-25
- **Final completion:** 2024-05-23
- **Target enrollment:** 1486 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01772472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01772472, "A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01772472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*